T-CURX
Latest round
- Series A
Last raised
- Nov 2025
Total raised
- $20M
Investors
- 6
About T-CURX
T-CURX GmbH, headquartered in Wurzburg, Germany, specializes in innovative personalized immunotherapies leveraging advanced CAR-T cell technology to combat various cancers. Founded in 2017, T-CURX GmbH operates in the field of personalized immunotherapies for cancer treatment., HighLight Capital, and i&i Bio. There is no information on previous pivots or subsidiaries. Details on the founder's history are not available. T-CURX specializes in the development of personalized immunotherapies utilizing CAR-T cell technology. Their product offerings focus on engineered CAR-T cells designed to provide targeted, chemotherapy-free treatments for hematological cancers and solid tumors. The company utilizes advanced engineering techniques, including virus-free transposon-based genetic modification and a modular CAR format, to create tailored therapeutic solutions that enhance flexibility, efficacy, and safety. T-CURX serves healthcare providers and research institutions across Europe and North America, particularly targeting patients facing challenges with conventional CAR-T therapies due to high costs and operational complexities. T-CURX generates revenue primarily through partnerships with healthcare providers, research institutions, and pharmaceutical companies involved in cancer treatment. The company licenses its proprietary CAR-T technologies and engages in joint ventures for product development and commercialization. Revenue streams include milestone payments, royalties, and profit-sharing agreements linked to the success of their CAR-T therapies in clinical settings. The company is expected to expand its operations into new markets, targeting regions across Europe and North America to enhance accessibility to its innovative therapies.
Who invested in T-CURX
6 investors across 1 round
See all investors in T-CURX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 5, 2025
Amount
$20M
Investors
Questions about T-CURX
Who invested in T-CURX?
T-CURX has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has T-CURX raised?
T-CURX has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did T-CURX last raise money?
T-CURX's most recent round on record is a Series A, in Nov 2025.
What does T-CURX do?
T-CURX GmbH, headquartered in Wurzburg, Germany, specializes in innovative personalized immunotherapies leveraging advanced CAR-T cell technology to combat various cancers.
Where is T-CURX headquartered?
T-CURX is headquartered in Wurzburg, Germany.
Which VCs invest in companies like T-CURX?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at T-CURX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like T-CURX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.